Ocrelizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1313 publications

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Journal: Multiple sclerosis and related disorders

Published: April 10, 2026

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Journal: Ideggyogyaszati szemle

Published: March 28, 2026

Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis.

Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis.

Journal: European journal of dermatology : EJD

Published: March 23, 2026

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Journal: Annals of neurology

Published: March 17, 2026

Obinutuzumab (Gazyva) for lupus nephritis.

Obinutuzumab (Gazyva) for lupus nephritis.

Journal: The Medical letter on drugs and therapeutics

Published: March 07, 2026

Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.

Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.

Journal: Annals of neurology

Published: February 21, 2026

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 20, 2026

Reviewer Comment on Hunt et al. "A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort".

Reviewer Comment on Hunt et al. "A Retrospective Evaluation of Ocrelizumab and Rituximab Discontinuation in a Real-World Patient Cohort".

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: February 19, 2026

Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.

Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 10, 2026

Beyond relapse control: motor and cognitive subclinical progression in RRMS -a real-world longitudinal study of ocrelizumab and interferon beta.

Beyond relapse control: motor and cognitive subclinical progression in RRMS -a real-world longitudinal study of ocrelizumab and interferon beta.

Journal: Acta neurologica Belgica

Published: January 22, 2026

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review.

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review.

Journal: Cureus

Published: January 20, 2026

Ocrelizumab in a difficult-to-treat rheumatoid arthritis patient.

Ocrelizumab in a difficult-to-treat rheumatoid arthritis patient.

Journal: Clinical and experimental rheumatology

Published: January 15, 2026

Showing 1-12 of 1,313

Last Updated: 04/28/2026